AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug
29-08-2017
Takeda enters $100m licensing agreement with Tesaro
01-08-2017
Jonathan Weiss / Shutterstock.com
Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Takeda, Par Pharmaceuticals, US District Court for the District of Massachusetts, KPH Healthcare Services, Kinney Drugs
